Kill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows Potential
Portfolio Pulse from Vandana Singh
IN8bio Inc (NASDAQ:INAB) revealed promising preclinical data for its INB-300 candidate from the nsCAR platform, showing improved selectivity in targeting leukemia cells while preserving healthy tissues. The data, presented at the AACR Annual Meeting 2024, demonstrates the potential of nsCAR to offer a wider therapeutic window and reduce off-tumor killing. The study highlighted the nsCAR constructs' ability to significantly enhance tumor-killing capability against leukemia cells without harming healthy cells, leading to a 9% increase in INAB stock in the premarket session.
April 10, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio Inc's INB-300 shows potential in targeting leukemia cells selectively, preserving healthy tissues, and demonstrating a significant increase in tumor-killing capability. This positive preclinical data led to a 9% increase in INAB stock in the premarket session.
The positive preclinical results for IN8bio's INB-300 demonstrate a significant advancement in leukemia treatment, highlighting the potential of the nsCAR platform to offer a safer and more effective therapy. The data's presentation at a prestigious conference and the subsequent stock price increase reflect the market's optimistic view on the company's future prospects and the potential impact of INB-300 on its financial performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100